EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Efficacy and safety of novel anticoagulant therapies in patients with chronic kidney disease—a systematic review and meta-analysis

Ernesto Calderon Martinez iD, Camila Sanchez Cruz, Edna Y Diarte Acosta, Daniel Alejandro Aguirre Cano, Ana Maria Espinosa, Diana Othón Martínez, Flor Furman, Sebastian Obando Vera

Journal of Nephrology · 2025

DOI: 10.1007/s40620-024-02130-3 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Nephrology, 2025. Verfasst von Ernesto Calderon Martinez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Universidad Nacional Autónoma de México, Ciudad de Mexico, México. ernestocalderon.mtz@gmail.com. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Anticoagulants, Thromboembolism. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic Kidney Disease (CKD) significantly increases the risk of cardiovascular diseases, including atrial fibrillation, which usually requires anticoagulant therapy. The effectiveness and safety of direct oral anticoagulants compared to vitamin K antagonists in patients with CKD remain insufficiently studied, particularly in the more advanced stages.

Methods

This systematic review, registered in PROSPERO (CRD42023410192), adhered to PRISMA guidelines and included randomized clinical trials and cohort studies comparing direct oral anticoagulants and vitamin K antagonists in CKD patients. Major databases were searched, and studies were selected based on strict inclusion criteria. A meta-analysis was performed using random-effects models.

Results

Twenty-three studies with a total of 465,673 CKD patients were included. Direct oral anticoagulants showed a significant reduction in major bleeding events compared to vitamin K antagonists (Relative Risk [RR] = 0.62, 95% Confidence Interval: 0.49–0.79, p < 0.01) and a non-significant trend toward reducing thromboembolic events (RR = 0.69, 95% Confidence Interval: 0.43–1.14, p = 0.11). Furthermore, direct oral anticoagulants were associated with a significant reduction in all-cause mortality (RR = 0.63, 95% Confidence Interval: 0.43–0.91, p = 0.02).

Conclusion

Direct oral anticoagulants may offer a safe alternative to vitamin K antagonists in CKD patients, particularly in terms of reducing bleeding risks and potentially improving survival. However, their role in preventing thromboembolic events remains uncertain, highlighting the need for further research, especially in patients with advanced CKD and kidney failure. Graphical abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicAnticoagulantsThromboembolismHumansHemorrhageVitamin KAdministration, OralTreatment OutcomeRisk FactorsAtrial Fibrillation

Stichwörter der Autor:innen

AnticoagulationChronic kidney diseaseDirect oral anticoagulantsVitamin K antagonists

Substanzen

AnticoagulantsVitamin K

Autor:innen und Institutionen

  • Universidad Nacional Autónoma de México, Ciudad de Mexico, México. ernestocalderon.mtz@gmail.com.
  • Universidad Nacional Autónoma de México, Ciudad de Mexico, México.
  • Universidad Autónoma de Sinaloa, Sinaloa, México.
  • Universidad de Monterrey, Monterrey, México.
  • Univesidad Nacional de Loja, Loja, Ecuador.
  • University of Texas RGV, Edinburg, TX, USA.

ORCID-Profile: Ernesto Calderon Martinez

Zitieren

APA

Calderon Martinez, E., Sanchez Cruz, C., Diarte Acosta, E. Y., Aguirre Cano, D. A., Espinosa, A. M., Othón Martínez, D., Furman, F., & Obando Vera, S. (2025). Efficacy and safety of novel anticoagulant therapies in patients with chronic kidney disease—a systematic review and meta-analysis. Journal of Nephrology. https://doi.org/10.1007/s40620-024-02130-3

Vancouver

Calderon Martinez E, Sanchez Cruz C, Diarte Acosta EY, Aguirre Cano DA, Espinosa AM, Othón Martínez D, et al. Efficacy and safety of novel anticoagulant therapies in patients with chronic kidney disease—a systematic review and meta-analysis. Journal of Nephrology. 2025. doi:10.1007/s40620-024-02130-3

BibTeX
@article{CalderonMartinez2025,
  author = {Calderon Martinez, Ernesto and Sanchez Cruz, Camila and Diarte Acosta, Edna Y and Aguirre Cano, Daniel Alejandro and Espinosa, Ana Maria and Othón Martínez, Diana and Furman, Flor and Obando Vera, Sebastian},
  title = {Efficacy and safety of novel anticoagulant therapies in patients with chronic kidney disease—a systematic review and meta-analysis},
  journal = {Journal of Nephrology},
  year = {2025},
  doi = {10.1007/s40620-024-02130-3}
}
Kostenlos starten →